
DermatologyIL-23 inhibitiontildrakizumab
Reversing Epigenetic Aging in Psoriasis: The Impact of Tildrakizumab over 52 Weeks
By MedXY|Aug 26, 2026
This study demonstrates that tildrakizumab, an IL-23 inhibitor, partially reverses accelerated epigenetic aging in psoriasis patients, highlighting a novel aspect of biologic therapy beyond skin inflammation control.